Oltipraz and related dithiolethiones are an important class of chemopreventive agents. Studies were undertaken to identify cancer chemopreventive dithiolethiones more active than oltipraz. Largely based upon enzyme induction activities in vitro, 17 dithiolethiones, including oltipraz, were analyzed for their ability to induce hepatic phase II enzyme activities in vivo. Of these compounds, 15 produced greater induction of NAD(P)H:quinone reductase and 11 yielded greater induction of glutathione S-transferase than oltipraz. All 17 dithiolethiones were then tested for their ability to inhibit acute hepatotoxicity by aflatoxin B 1 (AFB 1 ), which previously has been shown to be an intermediate predictor of chemopreventive activity. Rats were pretreated with dithiolethiones (0.3 mmol/kg body wt, three times a week per os) and challenged with two acutely toxic doses of AFB 1 (0.5 mg/kg body wt, once daily for two successive days per os). Inhibition of hepatotoxicity was measured by changes in body weight gain during AFB 1 challenge, reduction in levels of hepatic enzymes in serum and diminution of bile duct cell proliferation. Nine dithiolethiones spanning a range of responses in this toxicity screen were further tested for their ability to prevent AFB 1 -induced tumorigenicity, as assessed by a reduction in hepatic burden of putative preneoplastic foci. Six dithiolethiones were found to be considerably more effective than oltipraz in preventing AFB 1 -induced tumorigenesis. In general, dithiolethiones that were very effective in inhibition of acute hepatotoxicity were also found to be effective in prevention of hepatic tumorigenesis.
Introduction
Dithiolethiones offer considerable promise as cancer chemoprevention drugs. For example, oltipraz [2] (see Table I for Abbreviations: ADT, 5-(4-methoxyphenyl)-3H-1,2-dithiole-3-thione; AFB 1 , aflatoxin B 1 ; ALT, alanine aminotransferase; BDC, bile duct cells; BrdU, bromodeoxyuridine; D2T, 1,3-dithiole-2-thione; GST, glutathione S-transferase; GST-P, placental form of GST; QR, NAD(P)H:quinone reductase; r, Pearson product-moment correlation coefficient; r s , Spearman rank correlation coefficient; SDH, sorbitol dehydrogenase. chemical names and corresponding identification numbers) is an effective chemopreventive agent in rodent models of experimental carcinogenesis in target organs such as the pancreas, lung, forestomach, colon, urinary bladder, trachea, liver, mammary gland and skin (1 and references therein). Oltipraz has advanced through Phase I clinical trials to determine its pharmacokinetics and dose-limiting side effects during chronic administration to humans (2, 3) . A short-term Phase IIa clinical intervention trial has been completed recently in Qidong, Jiangsu Province, People's Republic of China, to define a dose and schedule of oltipraz [2] for reducing levels of validated biomarkers of exposure to the human hepatocarcinogen aflatoxin B 1 (AFB 1 ) (4) and to characterize dose-limiting toxicities (5) .
In humans, two dithiolethiones are known to possess pharmacological properties other than cancer chemoprevention. For example, oltipraz [2] was originally used as an investigational drug for the treatment of schistosomiasis. Single oral doses of oltipraz [2] have achieved cure rates of Ͼ90% in field trials (6) . 5-(4-Methoxyphenyl)-3H-1,2-dithiole-3-thione (ADT) is used currently as a choleretic and to stimulate salivary secretion and is marketed as an over-the-counter drug in many countries (7) . Thus, general tolerance of dithiolethiones and their acceptance in humans has been examined.
Oltipraz [2] and other dithiolethiones are potent inducers of enzymes involved in the maintenance of the reduced glutathione pools as well as enzymes involved in electrophile detoxication, such as NAD(P)H:quinone reductase (QR), epoxide hydrolase, UDP-glucuronosyl transferase and glutathione S-transferase (GST) (8) . The enhancement of electrophile detoxification through induction of phase II enzymes has been recognized as a characteristic action of many chemopreventive agents (9) . In contrast to marked induction of phase II enzymes, cytochrome P 450 levels and other phase I enzyme activities were only slightly elevated by oltipraz [2] (10) .
Oltipraz affords protection against acute and chronic hepatotoxicity. Pretreatment of rats or mice with oltipraz [2] resulted in the inhibition of acute hepatotoxicity of carbon tetrachloride (11), acetaminophen (11), allyl alcohol (12) and AFB 1 (13, 14) .
Mechanisms of chemoprevention by dithiolethiones are not fully understood. With oltipraz [2] , the enhancement of carcinogen detoxification pathways appears to be a major component of prevention against AFB 1 hepatocarcinogenesis (15,16). We have synthesized or obtained over 60 dithiolethiones and other chemically related compounds with the objective of identifying more effective chemopreventive compounds as well as some important chemical structural motifs that confer chemoprevention. These structure-activity studies might help to clarify the mechanism by which dithiolethiones inhibit carcinogenesis. For example, our initial anti-tumorigenesis studies of a few dithiolethiones showed that treatment with 0.1 or 0.3 mmol/kg body wt [1] , [3] , ADT or oltipraz [2] resulted in the inhibition of preneoplastic lesions induced by AFB 1 , while treatment with 1,3-dithiole-2-thione (D2T), which lacks the 3H-1,2-dithiole-3-thione nucleus, was not effective in reducing the focal burden (14) . The chemical structures of ADT and D2T are shown in Figure 1 . At both doses of dithiolethiones tested, [1] was more effective at cancer chemoprevention than [3] and these two were followed by ADT and oltipraz [2] , which were approximately equally effective.
The primary objective of the present studies was to identify other dithiolethiones with chemopreventive activity greater than oltipraz [2] . Additionally, we wanted to confirm that those dithiolethione analogs that effectively induce detoxification pathways and inhibit AFB 1 toxicity were indeed effective in the chemoprevention of AFB 1 tumorigenicity.
Materials and methods
Chemicals and animals AFB 1 was obtained from Aldrich (Milwaukee, WI) and was dissolved in tricaprylin for administration by gastric intubation. Except for [13] , all dithiolethiones were known compounds and were prepared by the literature procedure or as described elsewhere (18, 19) . Compound [13] was prepared from the known 3H-1,2-dithiole-3-thioxo-4-carboxylic acid ethyl ester (R.L.Hodgson and E.J.Smutny, US patent 3 394 146, 1968) by acetic/sulfuric 1610 acid hydrolysis to the corresponding acid, followed by conversion to the amide with ammonium acetate and 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate. Full experimental details of this preparation will be published elsewhere (T.J.Curphey, manuscript in preparation). The identity of all dithiolethiones was established by correspondence of physical properties to published values and by 1 H-and 13 C-NMR spectroscopy. Purity was assessed by TLC and HPLC and was Ͼ95% in all cases, as judged by integrated UV absorbance in HPLC chromatograms. The dithiolethione analogs were gavaged as a finely ground powder suspended in a saturated and viscous solution of sucrose (14) .
Serum alanine aminotransferase (ALT) and sorbitol dehydrogenase (SDH) activities were measured spectrophotometrically using diagnostic kits (Sigma, St Louis, MO). Bromodeoxyuridine (BrdU) was purchased from Sigma. AntiBrdU monoclonal antibody was supplied by Becton Dickinson (San Jose, CA) and immunostaining of BrdU-labeled DNA was performed with the peroxidase-anti-peroxidase detection system (Signet Laboratories, Dedham, MA). The primary GST Yp antibody was purchased from Biotrin International (Dublin, Ireland) and its localization was accomplished with a PAP immunoenzymatic staining kit (Dako, Carpinteria, CA).
Male F344 rats (90-100 g) were purchased from Charles River Breeding Laboratory (Wilmington, MA). Animals were fed pelleted purified AIN-76A diet (Harlan, Madison, WI), but without the dietary antioxidant ethoxyquin. Rats were allowed 5 days to acclimate to the facilities before treatment.
Strategy for selection of dithiolethione analogs
Over a score of dithiolethiones have been evaluated for phase II enzyme induction in Hepa 1c1c7 cells in culture (20) . A subset from this in vitro screen plus a few additional analogs were selected for evaluation and are listed in Table I . Chemical structures of the dithiolethiones studied herein are shown in Figure 2 . Several considerations were used in the selection of dithiolethione analogs for the study. Compounds [1] and [3] have already been shown to be more active than oltipraz [2] in chemoprevention studies against the formation of AFB 1 -induced foci (14) and were tested again. Compounds [10] and [11] have been shown to reduce AFB 1 adduction to hepatic DNA, implying chemopreventive activity (15) . Four pairs of positional isomers (i.e. carbon 4 versus 5 of the dithiolethione ring system: [3] and [4] ; [5] and [6] ; [10] and [11] ; [12] and [13] ) were included for structure-activity comparisons. For an additional comparison of aliphatic side chain size, we added compound [7] and two analogs with a fused ring system of either five [8] or six carbons [9] . Four additional analogs ( [14] , [15] , [16] and [17] ) were chosen to represent other types of substituents.
Induction of phase II enzymes
Rats were gavaged with dithiolethione analogs (1 mmol/kg body wt) and killed 48 h following treatment. Phase II enzymes were measured as described previously (21) . Briefly, livers were homogenized in 4 vol (w/v) 50 mM Tris-HCl buffer, pH 7.0, containing 0.25 M sucrose. Homogenates were centrifuged at 10 000 g for 15 min and the obtained supernatant was then centrifuged at 105 000 g for 60 min. The resulting fluid was used for GST assay, using 1-chloro-2,4-dinitrobenzene as substrate (22) , and QR assay (23) .
Acceptance of test compounds
To precisely know the dose and because of limited availability of many compounds, treatment with the putative chemopreventive agents was by gavage. In a preliminary experiment (14) , growth of the rats during a 1 week period was limited by some dithiolethione analogs at doses Ͼ0.3 mmol/kg body wt. Because of generally accepted concern that inhibition of growth would modify the carcinogenic response (24-26), we assessed growth when the dosage was at the rate of every other day over a 6 day period. This schedule approximates the timing and the total dose of oltipraz [2] in previous studies where it was fed in the diet (15) (16) (17) . This protocol has been described in detail previously (14) . Briefly, groups of four rats received three doses of an analog at 0.3 mmol/kg body wt by gavage every other day. During this time, general acceptance and tolerance of dithiolethiones by the animals were assessed.
Protection from acute hepatotoxicity of AFB 1 Protection against AFB 1 toxicity was assessed as previously described (14) . Beginning 2 days following the last treatment with dithiolethiones, rats were challenged with two acutely toxic doses of AFB 1 (0.5 mg/kg body wt, 24 h apart). Because of the large number of compounds tested, four replicate experiments were carried out, each with its own AFB 1 and no-AFB 1 control groups. ALT and SDH activities and BrdU incorporation into bile duct cells (BDC) were measured. Rats were given two doses of BrdU (100 mg/kg body wt i.p., 5 and 2 h prior to autopsy) and killed 28 h after the second dose of AFB 1 . A minimum of 350 BDC were counted in a total of 20-30 periportal triads. The labeling index was calculated by dividing the number of labeled nuclei by the total number of nuclei counted. No single parameter clearly characterizes hepatotoxicity elicited by AFB 1 ; therefore, we used several facile measures. For each of four assessments of toxicity, the rankings of the compounds were approximately similar, therefore, for simplicity of presentation, an overall sum of the ranks was calculated.
Inhibition of hepatic tumorigenesis
Nine dithiolethiones were evaluated in a tumorigenesis experiment. Compounds [1] , oltipraz [2] and [3] have been previously evaluated (14) and were included for comparative purposes. Based upon the ability to protect against AFB 1 toxicity, five analogs better and one worse than oltipraz [2] were selected.
Dithiolethiones were gavaged at 0700-0800 h, Monday, Wednesday and Friday for three successive weeks. AFB 1 (25 µg/rat/day, five days a week for two successive weeks) was given by gavage at 1300 h, starting on Monday of the second week. As in the acute toxicity experiment above, rats were exposed to the dithiolethiones beginning 1 week prior to exposure to AFB 1 . All rats were killed 5 weeks after the end of the AFB 1 treatment. Livers were analyzed by light microscopy for foci expressing the placental form of GST (GST-P) (27) . Details of these protocols have been published (14) .
Statistical analysis
Because the analogs were tested in four separate experiments, all toxicological data are presented as a percentage of inhibition of toxicity. Body weight and GST-P-positive focal data were analyzed by one way ANOVA followed by Bonferroni multiple comparison tests. The variances for two variables, the number of foci/cm 3 and the volume percentage of the liver occupied by the GST-P-positive foci, were found to be approximately proportional to the size of the variable. Therefore, in order to stabilize the variance, the data for these variables were logarithmically transformed prior to ANOVA. The Spearman rank correlation coefficient (r s ) was used to compare the in vivo enzyme activities or toxicological indices with the GST-P focal burden. Additionally, in Figure 3 , the Pearson product-moment correlation (r) was used to compare focal volume percent and in vivo enzyme activities.
Results

Induction of phase II enzymes
Results of the hepatic enzyme assays are presented in Table  I . Of 17 dithiolethiones tested, 15 induced hepatic QR activity 1611 greater than oltipraz [2] , with only compound [11] showing less response. Eleven analogs were better inducers of hepatic GST activity than oltipraz [2] .
Protection from acute hepatotoxicity of AFB 1 Rats in the groups receiving [1] , [8] and [13] continued to gain weight even after the challenge with toxic doses of AFB 1 (Table II) . Additionally, pretreatment with eight other compounds, [3] , [4] , [5] , [6] , [7] , [9] , [11] and [17] , resulted in greater protection (i.e. less loss of body weight) from the toxic effects of AFB 1 than afforded by oltipraz [2] .
Except for [15] , pretreatment with all dithiolethiones protected against AFB 1 cytotoxicity, i.e. these dithiolethiones resulted in less release of SDH and ALT to the serum as compared with the AFB 1 -treated group. As with weight gain, compounds [1] , [8] and [13] afforded the greatest protection (Table II) .
For rats not exposed to AFB 1 , the BDC labeling was low, in the range 0.3-1.1%, and labeling increased to 31-36% with AFB 1 treatment. This high BDC proliferation rate was reduced by pretreatment with all dithiolethiones except for [3] , [12] , [16] and [17] (Table II) . Again, compounds [1] , [8] and [13] afforded the greatest protection from this classic effect of AFB 1 .
Using all four toxicological indices (i.e. growth during AFB 1 treatment, level of each hepatic enzyme in blood and BDC proliferation), all 17 analogs were ranked (Table II) . Ten dithiolethiones were found to be more effective in inhibiting AFB 1 -induced hepatotoxicity than oltipraz [2] using the sum of ranks as an indicator.
Previously, we had shown that a strong correlation existed between preventing hepatotoxicity and chemoprevention of a Four rats per group. Inhibition as compared with the AFB 1 -treated group. b Mean value for 6 days pretreatment with dithiolethiones. c Mean value for 2 days treatment with AFB 1 . In the AFB 1 -treated group body weight loss was 3 g/day. d For all 17 dithiolethiones, each measure of toxicity (i.e. growth during AFB 1 treatment, ALT and SDH activities and BDC proliferation) was ranked from least to most severe and these four ranks were summed. The lowest sum of ranks corresponds to the greatest protection. e All four rats experienced weight loss and two rats that received [15] had such a substantial weight loss (up to 25% of pre-dose weight) that they were not treated with AFB 1 . Analysis of their serum samples indicated no signs of hepatic toxicity. The remaining two rats were challenged with AFB 1 as described. f By convention, tie values are indicated as half way between the two possible ranks.
1612 tumorigenesis (14) . As seen in Table II, 10 dithiolethiones were more effective and six were less effective than oltipraz [2] in mitigating against AFB 1 toxicity. Based on their ability to block toxicity, [3] and [12] were predicted to have chemopreventive activity less than oltipraz [2] , while [1] and [5] , [6] , [7] , [8] and [9] were expected to have activity greater than oltipraz [2] . These nine dithiolethiones were subsequently tested for their ability to protect against AFB 1 -induced hepatic tumorigenesis.
Inhibition of hepatic tumorigenesis
In this experiment, all rats grew at comparable rates except for those in groups [7] and [12] , where growth retardation during AFB 1 treatment was similar to the AFB 1 -treated group (data not shown). However, at termination of the experiment, the mean body weight in all groups did not differ significantly from the mean body weight in the AFB 1 -treated group nor did the liver weights differ (data not shown). Treatment with all dithiolethiones resulted in significant inhibition of AFB 1 -induced tumorigenesis (Table III) . Except for the oltipraz [2] and [9] groups, in which all rats had foci, at least one of eight animals in each of the other dithiolethione groups had no detectable GST-P-positive foci. Foci were only very rarely encountered in the no-AFB 1 control rats, whereas in the livers of the AFB 1 -treated rats,~8 foci/cm 2 tissue were observed. As is already well documented (28), statistical analysis of the observed focal data is not appropriate, therefore, these data were first subjected to morphometric transformation.
Treatment with [1] , [3] and [5] , [6] , [7] and [8] significantly decreased the number of GST-P-positive foci/cm 3 compared with the AFB 1 -treated group, whereas treatment with oltipraz [2] , [9] and [12] did not. While it seemed that, except for [1] and [7] , treatment with dithiolethiones reduced the size of the GST-P-positive foci, the difference in focal diameter between a Mean Ϯ SE, n ϭ 8, except for the AFB 1 -treated group, where n ϭ 5. b On average 7-9 cm 2 liver/animal were analyzed, except for the AFB 1 -treated group, where because of the large number of foci observed only 2-3 cm 2 were analyzed. c The extent of protection was ranked based on the volume percentage of the liver occupied by the GST-P-positive foci. The lowest rank corresponds to the greatest chemoprevention. d Statistically different (P Ͻ 0.05) from the no-AFB 1 control group. e Statistically different (P Ͻ 0.05) from oltipraz [2] . f Statistically different (P Ͻ 0.05) from the AFB 1 -treated group. g Statistically different (P Ͻ 0.05) from each other.
the groups was not statistically significant. The volume percentage of liver occupied by GST-P-positive foci (or simply focal volume percent) is analogous to tumor burden. This parameter is generally considered the most robust measure of the foci (28) . Focal volume percent in the dithiolethione groups as compared with that in the AFB 1 -treated group revealed that all analogs tested afforded significant reduction in focal burden, with reductions of Ͼ90% for all analogs. However, oltipraz [2] , [9] and [12] did not afford as extensive a reduction in focal burden as did the other dithiolethiones. The focal volume percent for the analogs was ranked from the most effective inhibitor, analog [1] , to the least effective, analog [12] (Table III) . Except for [3] , the rank order based on acute toxicity screening was identical to the rank order based on inhibition of tumorigenesis. Moreover, volume percent of the GST-P-positive foci was highly significantly inversely correlated with all four indices of acute hepatic toxicity (for weight change during the AFB 1 treatment r s ϭ -0.894, P Ͻ 0.0005; for SDH r s ϭ -0.941, P Ͻ 0.0001; for ALT r s ϭ -0.831, P Ͻ 0.005; for BDC labeling index r s ϭ -0.756, P Ͻ 0.01). A robust inverse correlation between in vivo phase II enzyme induction activities and chemoprevention was also observed (for QR r s ϭ -0.879, P Ͻ 0.005; for GST r s ϭ -0.786, P Ͻ 0.05).
Discussion
The first objective of these studies was successful. At least six dithiolethiones with chemopreventive properties that exceeded oltipraz [2] have been identified (Table III) . Herein, we have confirmed our previous observation that compounds [1] and [3] are more efficacious than oltipraz [2] (14, 21) . Additionally, four new, promising dithiolethiones were identified, [5] , [6] , [7] and [8] . Based solely upon the toxicological screening data of Table II, [13] would likely have been more efficacious than oltipraz [2] , but we did not have enough of it synthesized for it to be fully tested. The conditions of testing to identify these six dithiolethiones were stringent, in that we purposefully tested these dithiolethiones at equal molar doses against an extremely effective dose (0.3 mmol/kg body wt) of oltipraz [2] . In other words, a successful compound had to be better than oltipraz, which itself reduced the AFB 1 -induced focal burden by Ͼ90%. As seen previously, this reduction in focal volume percent was attended by a decrease in the number of foci and less often by a decrease in the mean focal size (17, 21) . This outcome further supports previous studies indicating that oltipraz effects the initiation events of carcinogenesis and not the events that primarily drive the growth of foci (15) .
Our strategy for identifying compounds with greater chemoprotective properties than oltipraz [2] relied upon a tiered approach. Candidate dithiolethiones with activity greater than oltipraz [2] were initially identified from in vitro data on the induction of QR and GST (20) and from their ability to induce in vivo hepatic QR and GST (T.J.Curphey, manuscript in preparation). Based on these studies, we selected 16 dithiolethiones (see Table I ), of which most showed greater induction of hepatic QR and/or GST than that engendered by oltipraz [2] . To further prioritize the selected compounds, we employed a strategy used previously (14) . Specifically, the candidate dithiolethiones were initially tested for their ability to mitigate against the toxic effects of AFB 1 . The rationale behind this approach is our observation that dithiolethiones that reduce the acute toxic effects of AFB 1 are the same ones that are chemopreventive against AFB 1 -induced hepatic tumorigenesis (14) . From those chemicals that protected against the acute toxic effects of AFB 1 , we selected several active dithiolethiones and other interesting structural analogs (see discussion below) to test their ability to prevent AFB 1 -induced hepatic tumorigenesis. This tiered approach proved very effective.
Of the compounds evaluated for their chemopreventive properties, the GST and QR values from in vivo enzyme induction (Table I) were inversely correlated with the focal volume percent values (Table III) . Figure 3 graphically depicts the highly predictive nature of induction of phase II enzyme activity by dithiolethiones and implies that protection against, at least, these early events of AFB 1 hepatic carcinogenesis largely confers chemoprevention. A wealth of evidence testifies that agents that increase detoxification pathways for AFB 1 would be chemopreventive (21) . Similarly, strong correlations were seen between indices of hepatotoxicity and focal volume percent. While the nature of the relationship between the hepatotoxic effects and tumorigenic effects of AFB 1 is largely unknown, there is little doubt that chemicals that ameliorate acute toxicity also protect against tumor development. For example, upon challenge with acutely toxic doses of AFB 1 , the parent dithiolethione [1] afforded complete protection against the growth inhibitory effects of AFB 1 , whereas the rats receiving only AFB 1 lost weight (Table II, footnote c) . Previously, we observed that both oltipraz [2] and the parent structure [1] prevented these acute toxic effects of AFB 1 (13, 14) . Furthermore, SDH and ALT activity in the sera of these rats were identical to the rats that did not receive AFB 1 . Classically, AFB 1 toxicity is attended by proliferation of BDC (29) (30) (31) . The parent dithiolethione [1] largely prevented all AFB 1 -induced BDC proliferation and corroborated previous observations in this identical animal model (14) . In contrast, oltipraz [2] provided much less protection as assessed by all four markers of hepatic toxicity. The sum of ranks of these four toxicological markers placed oltipraz [2] in the midst of the selected compounds (Table II) .
Mechanistic insights of exactly how the dithiolethiones blunt tumorigenesis are certainly not clear (32, 33) . Identification of chemical structural motifs that confer chemoprevention would be highly desirable and certainly would aid in elucidating mechanisms of chemoprevention. We can make only tentative observations regarding structural activity. As already demonstrated and largely confirmed herein, both the parent dithiolethione [1] and the 5-methyl member [3] were more effective than oltipraz [2] in alleviating hepatic toxicity of AFB 1 and inhibiting development of foci (14) . For an unexplained reason, [3] was less effective in protecting against acute toxicity in this study than in our previous study (14) , although the comparison between this and the former study for protection against foci development yielded identical results and showed [3] to be nearly as good as [1] . Several other simple alkylsubstituted dithiolethiones (e.g. [5] - [8] ) were more active than oltipraz [2] . These aforementioned dithiolethiones are certainly more lipophilic than oltipraz. This is especially interesting in the light of the report by French workers (34) who, using our previously published in vitro data (20) , concluded that less lipophilic dithiolethiones were the most active chemopreventive agents. Our findings in the present instance lend little support to this generalization, which was in fact based not on the full set of our in vitro data, but on a carefully selected subset (five out of seven disubstituted dithiolethiones, the remaining two excluded because of their failure to fit the correlation). Indeed, a more extensive structure-activity study of enzyme induction in vivo (T.J.Curphey, manuscript in preparation) has failed to find much correlation between lipophilicity and biological activity of dithiolethiones. It appears as if the position of this addition (i.e. carbon 4 or 5 of the ring) may not be critical, since compounds [5] and [6] protected against AFB 1 -induced foci to similar extents. The difference in biological activity between compounds [8] and [9] was quite large (Tables I-III) . This observation is particularly interesting considering that the aliphatic addition to the parent structure differed only by a single carbon (Figure 2) . It is not possible to know at what level these structural changes render their action. The effectiveness of these dithiolethiones could 1614 be explained in a trivial sense by differences in biological stability, absorption and metabolism or these effects could be manifestations of differing molecular and/or chemical interactions at some critical target.
Based upon the inhibition of putative preneoplastic foci, we have identified several dithiolethiones possessing cancer chemoprevention activity equal to or greater than oltipraz [2] . Furthermore, we have defined a series of short-term toxicological tests to identify candidate chemopreventive agents to mitigate against AFB 1 carcinogenicity.
